Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | LPL | P06858 | 1/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956809 | 0.79 | RAB9A (0.51) | ENPP2LMNAALDH1A1SMN1; SMN2HTT | |
| SCHEMBL957571 | 0.79 | RAB9A (0.51) | ENPP2LMNAALDH1A1SMN1; SMN2HTT | |
| SCHEMBL12077562 | 0.79 | HTT (0.63) | ENPP2LMNAALDH1A1SMN1; SMN2HTT | |
| SCHEMBL3845008 | 0.76 | PGR (0.57) | ENPP2LMNAALDH1A1HTTMAPT | |
| SCHEMBL6035346 | 0.76 | ENPP2 (0.47) | ENPP2SMN1; SMN2CA2LPLLIPG | |
| Potassium Ion SCHEMBL1577462 | 0.76 | LMNA (0.59) | LMNAALDH1A1SMN1; SMN2HTTMAPT | |
| SCHEMBL21244024 | 0.76 | LMNA (0.59) | LMNAALDH1A1SMN1; SMN2HTTMAPT | |
| SCHEMBL8675 | 0.76 | ENPP2 (1.00) | ENPP2KDM4ECA2LPLLIPG | |
| SCHEMBL1104973 | 0.76 | LMNA (0.59) | ENPP2LMNAALDH1A1SMN1; SMN2HTT | |
| SCHEMBL20646117 | 0.75 | ENPP2 (0.67) | ENPP2LMNAALDH1A1KDM4ECA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | claimed |
| US-20250082593-A1 | HALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | SYNTARA LIMITED (AU) | 2025-03-13 | — | — | US | disclosed |
| US-12178791-B2 | Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof | SYNTARA LIMITED (AU) | 2024-12-31 | — | — | US | disclosed |
| EP-3829520-B1 | HALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | SYNTARA LTD (AU) | 2024-11-27 | — | — | EP | disclosed |
| CN-114555588-B | Quinazoline compounds as AXL inhibitors | 南京正大天晴制药有限公司 | 2024-08-06 | — | — | CN | disclosed |
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| EP-4288437-A1 | MAP4K1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| EP-3741757-B1 | DIHYDROINDOLIZINONE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2023-07-26 | — | — | EP | disclosed |
| CN-111630052-B | Dihydroindazinone derivatives | 第一三共株式会社 | 2023-04-18 | — | — | CN | disclosed |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| WO-2007025575-A1 | O-HYDROXY- AND O-AMINO BENZAMIDE DERIVATIVES AS IKK2 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20060258670-A1 | New phenylpyridylpiperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-11-16 | — | — | US | disclosed |
| US-20060084651-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2006-04-20 | — | — | US | disclosed |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | disclosed |
| US-20060025460-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | US | disclosed |
| WO-2006009869-A1 | COUMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| EP-1606266-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004084813-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-10-07 | — | — | WO | disclosed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12178791-B2 | Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof | LOX, DAO, LOXL1 | ENPP2 203/4885LMNA 992/4885ALDH1A1 303/4885 |
| US-20060258670-A1 | New phenylpyridylpiperazine compounds | HRH4, HRH3, HRH2 | ENPP2 351/4885LMNA 4719/4885ALDH1A1 3223/4885 |
| US-20250082593-A1 | HALOALLYLAMINE SULFONE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | LOX, DAO, LOXL1 | ENPP2 203/4885LMNA 992/4885ALDH1A1 303/4885 |
| US-20240174683-A1 | MAP4K1 INHIBITORS | MAP3K4, MAP4K4, MAP4K1 | ENPP2 522/4885LMNA 2238/4885ALDH1A1 3841/4885 |
| US-20060025460-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | BCL3, BCL2, BCLAF1 | ENPP2 1029/4885LMNA 3700/4885ALDH1A1 3755/4885 |
| US-20060084651-A1 | Chemical compounds | STK25, MAP3K5, STK35 | ENPP2 1640/4885LMNA 2739/4885ALDH1A1 3276/4885 |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | GSK3A, GSK3B, PYGL | ENPP2 479/4885LMNA 114/4885ALDH1A1 2625/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | ENPP2 2460/4885LMNA 3182/4885ALDH1A1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.